To determine whether there is any relationship between basal pERK levels and the efficacy of Sorafenib on killing cells in vivo, pERK levels in different HCC patients were compared by immunohistochemistry (Fig. 2A) and western blot (Fig. 2B). The gene discussed is EIF2AK3; the disease is hepatocellular carcinoma.